The United Bio-technology (hengqin) Co., Ltd.
Clinical trials sponsored by The United Bio-technology (hengqin) Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New diabetes shot UBT38006 enters first human safety trial Results expected Oct 2026 (estimated)
- Could a new Weight-Loss drug play well with others? a trial investigates Results expected Dec 2026 (estimated)
- New weekly shot aims to reverse fatty liver damage Results expected Jun 2027 (estimated)
-
Can a weekly shot ease sleep apnea in obesity?
Disease control Not yet recruitingThis phase 3 trial tests whether UBT251, an investigational drug given as a weekly injection, can reduce breathing pauses during sleep in adults with moderate-to-severe obstructive sleep apnea who also have obesity. Participants continue their usual positive airway pressure (PAP)…
Phase 3 • Sponsor: The United Bio-Technology (Hengqin) Co., Ltd. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a weekly shot ease sleep apnea without a CPAP machine?
Disease control Not yet recruitingThis phase 3 trial is testing whether an investigational drug called UBT251 can reduce the severity of obstructive sleep apnea in people who are obese and do not use positive airway pressure (PAP) therapy. Participants will receive weekly injections of UBT251 or a placebo for 52 …
Phase 3 • Sponsor: The United Bio-Technology (Hengqin) Co., Ltd. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Weekly shot could help shed pounds in obesity trial
Disease control Not yet recruitingThis phase 3 study tests whether a weekly injection called UBT251 can help overweight or obese adults lose weight. Participants receive either the drug or a placebo for 52 weeks. The main goal is to measure the percentage change in body weight, with additional checks on waist siz…
Phase 3 • Sponsor: The United Bio-Technology (Hengqin) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC